Weekend News: Global Entry of Indian Pharmaceutical Industries


After the relaxing weekend we are back again! Oh! It seems lot has happened in Indian pharmaceutical sectors and it is ready to create a stir in the global market. Check this out and beat your Monday blues.

1. Zydus Cadila recieves FDA approval for carboplatin injection

Zydus cadila received marketing approval from US FDA for its carboplatin injectionIndian pharmaceutical company Zydus Cadila received marketing approval from US Food and Drug Association (FDA) for its carboplatin injection, 10mg/ml in 5ml, 15ml and 45ml used for cancer treatment in American market. Since the inception of the filing process in 2003-04 fiscal, the company already have more than 100 approvals and has filed over 280 Abbreviated new drug applications (ANDAs) so far.

2. Sun Pharma entry into Japan market

sun pharma acquired novartis'14 brands in japanIndia’s Sun Pharma marked its significant presence in Japan (World’s second largest drug market after US) by acquiring Novartis’ 14 brands for $293 million in Japan. These drugs have a combined annual revenues of $160 million known for the treatment of medical conditions in diverse therapeutic areas.

Dilip Shanghvi, managing director of Sun Pharma, said, “Japan is a market of strategic interest for us. This acquisition marks Sun Pharma’s foray into the Japanese prescription market and provides us an opportunity to build a larger product portfolio in the future.”

3. Sun Pharma alliance with AstraZeneca for anti-diabetic drugs 

sun pharma acquired novartis'14 brands in japanAnother news from Sun Pharma as it has entered into an alliance with the British-Swedishastrazeneca and sun pharma collaboration for anti-diabetic drugs multinational pharmaceutical company AstraZeneca for the promotion and distribution of the latest generation anti-diabetes drug dapagliflozin under the brand name “Oxra”. In addition to this Sun Pharma is currently seeking regulatory approval from Drug Controller General of India for promotion and distribution of combination dapagliflozin with metformin under brand name “Oxramet”. In a country of approximately 69.2 million diabetic patients this collaboration could project the drug dapagliflozin forward in the treatment of Type 2 diabetes in India.

sun pharma collaborations in 2016

4. Jubilant Life Sciences US arm get upto $22.6 million in an acquisition

Jubilant Innovation USA and Jubilant life sciencesJubilant Life Sciences’ US arm’s (in which company has an indirect investment) acquisition of a drug development firm fetched the company up to $22.6 millionJubilant Innovation USA will receive “an upfront payment of USD 4.6 million and contingent payments of up to USD 18 million based on the achievement of certain predetermined clinical and regulatory milestones from its 10 per cent interest as a limited partner in one of the venture funds specialized in seeding and investing in early stage drug discovery firms“, Jubilant Life Sciences said in a Bombay Stock Exchange (BSE) filing.

Featured image credit: Background Of Yellow Balls With Bingo Numbers © Photology1971 (Stock Photo ID: 71341471)

Leave a reply

Your email address will not be published. Required fields are marked *